Opinion|Videos|August 5, 2024
Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What is the potential role of value-based pricing models or alternative payment arrangements in improving access to CDK4/6 inhibitors for eligible patients?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Novel Iberdomide Regimen in RRMM
2
Iberdomide Approval Elevates MRD’s Role in Myeloma: Prerna Mewawalla, MD
3
AI Model Outperforms Apnea-Hypopnea Index in Predicting Sleep Apnea Mortality Risk
4
IL-17 Signaling Bridges Psoriasis and Cardiometabolic Risk, Review Finds
5